News Agency
Men's Weekly

CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

  • Written by PR Newswire

Key Highlights:

  • Excellent Safety Profile:  As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to show a favorable safety profile, with 23% incidence of Grade ≥3 Treatment-Related Adverse...

Read more: CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific...

Air Conditioner Sales Melbourne Helping You Choose The Right Cooling Solution

Creating a comfortable indoor environment often starts with choosing the right system, and that’s where air conditioner sales Melbourne become more than just a purchase decision. It’s about finding a solution that aligns with your space, lifestyle, and energy needs. With... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion